The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Does The Forecasted Market Size Of The Neurodegenerative Disorder Therapeutics Market Compare Between 2026 And 2030?
The neurodegenerative disorder therapeutics market size has seen strong growth in recent years. It is anticipated to increase from $21.66 billion in 2025 to $23.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.2%. The expansion observed in previous periods can be linked to the rising prevalence of neurodegenerative conditions, an expanding aging population, limited therapeutic options, increased awareness surrounding early diagnosis, and the development of hospital and neurology care infrastructure.
The neurodegenerative disorder therapeutics market size is expected to show significant growth in the upcoming period. It is forecast to grow to $34.13 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. This expansion over the forecast period is driven by factors such as the development of gene therapies, advances in monoclonal antibody treatments, the integration of AI-based diagnostics and monitoring, a rise in investment for clinical research and trials, and the expansion of personalized medicine and targeted therapeutics. Notable trends during this time include the increasing adoption of neuroprotective and neurorestorative therapies, a growing emphasis on symptom management and patient-centric care, an increase in clinical trials for novel neurodegenerative drugs, the broadening of personalized and targeted therapeutic approaches, and the integration of home care and remote monitoring solutions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp
Which Major Factors Are Contributing To The Development Of The Neurodegenerative Disorder Therapeutics Market?
Growing spending on research and development (R&D) for neurodegenerative disorder therapeutics is anticipated to boost the expansion of the neurodegenerative disorder therapeutics market. Governments and various organizations initiate R&D investments in neurodegenerative disorders due to several crucial factors, such as the rising incidence, considerable unmet patient needs, economic consequences, and global health objectives. For example, in March 2023, the Government of Canada, a federal administration, disclosed an investment of $38.3 million to advance research in neurodegenerative diseases. Consequently, continued investment in R&D for neurodegenerative disorder therapeutics is expected to fuel the market’s expansion in the foreseeable future.
How Is The Neurodegenerative Disorder Therapeutics Market Distributed Across Key Segments?
The neurodegenerative disorder therapeutics market covered in this report is segmented –
1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types
2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types
3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies
3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids
4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications
5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments
Which Trends Are Influencing The Expansion Of The Neurodegenerative Disorder Therapeutics Market?
Major companies operating in the neurodegenerative disorder therapeutics market are directing their efforts towards developing innovative treatment options, such as prodrug formulations, to improve the bioavailability, efficacy, and safety profile of Parkinson’s disease therapies. Prodrugs are inactive compounds that are metabolically converted into active drugs within the body, facilitating controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, launched PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for people living with advanced Parkinson’s disease. This therapy utilizes a soluble prodrug combination to provide continuous levodopa delivery, aiming to reduce motor fluctuations and enhance patients’ quality of life. This launch signifies a substantial advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and improving treatment adherence.
Who Are The Major Companies Operating In The Neurodegenerative Disorder Therapeutics Market?
Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.
Access The Complete Neurodegenerative Disorder Therapeutics Market Report:
Which Area Represents The Largest Portion Of The Neurodegenerative Disorder Therapeutics Market?
North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Neurodegenerative Disorder Therapeutics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp
Browse Through More Reports Similar to the Global Neurodegenerative Disorder Therapeutics Market 2026, By The Business Research Company
Neurology Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report
Interventional Neurology Devices And Equipment Market Report 2026
Neurosurgery Devices And Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model